Zentalis Pharmaceuticals Announces Julie Eastland Appointed Chief Executive Officer, President And Director; Scott Myers Appointed To The Board Of Directors As Chairperson
Zentalis Pharmaceuticals Announces Julie Eastland Appointed Chief Executive Officer, President And Director; Scott Myers Appointed To The Board Of Directors As Chairperson
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced changes to its executive leadership team to support the Company as it plans and executes registrational studies for its lead product candidate, azenosertib.Julie Eastland appointed Chief Executive Officer, President and Director
朱莉·伊斯特蘭德被任命爲首席執行官、總裁和董事
Ingmar Bruns, M.D., appointed Chief Medical Officer
英格瑪·布倫斯萬.D.被任命爲首席醫療官
Scott Myers appointed to the Board of Directors as Chairperson
斯科特·邁爾斯被任命爲董事會主席
SAN DIEGO, Nov. 13, 2024 (GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (NASDAQ:ZNTL), a clinical-stage biopharmaceutical company discovering and developing clinically differentiated small molecule therapeutics targeting fundamental biological pathways of cancers, today announced changes to its executive leadership team to support the Company as it plans and executes registrational studies for its lead product candidate, azenosertib.
聖地亞哥，2024年11月13日(GLOBE NEWSWIRE) -- Zentalis Pharmaceuticals, Inc. (納斯達克:ZNTL)是一家臨床階段的生物製藥公司，致力於發現和開發臨床上具有差異化的小分子治療藥物，針對癌症的基本生物通路。今天宣佈對其執行領導團隊進行更改，以支持公司規劃和執行其主要產品候選藥物azenosertib的註冊研究。
Julie Eastland has been appointed Chief Executive Officer, President and Director, succeeding Kimberly Blackwell, M.D., who will remain as a strategic advisor to the Board of Directors. Ms. Eastland is an accomplished biopharmaceutical executive with substantial leadership experience operating late-stage oncology companies. She previously served as Chief Executive Officer at Harpoon Therapeutics until the company's acquisition by Merck in early 2024. In addition to Ms. Eastland's appointment, Ingmar Bruns, M.D., has been appointed Chief Medical Officer. The Company also announced that Scott Myers has been appointed as Chairperson of the Zentalis Board of Directors.
朱莉·伊斯特蘭德已被任命爲首席執行官、總裁和董事，接替金伯莉·布萊克威爾萬.D.，後者將繼續擔任董事會的戰略顧問。伊斯特蘭德女士是一位傑出的生物製藥高管，在晚期腫瘤公司運營方面擁有豐富的領導經驗。她曾擔任harpoon therapeutics的首席執行官，直到公司於2024年初被默沙東收購。除伊斯特蘭德女士的任命外，英格瑪·布倫斯萬.D.也被任命爲首席醫療官。公司還宣佈斯科特·邁爾斯已被任命爲Zentalis董事會的主席。
譯文內容由第三人軟體翻譯。
